The content on this site is intended for healthcare professionals only
Anne Kramer speaks with ecancertv at Childhood Cancer 2016 about her work towards an improved line of CD 19 CAR T cells.
She describes how the single-chain variable fragment (scfv) could be a site of tumour-specific binding across multiple cancer types, and the cytotoxic capabilities of CAT CAR T cells.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Guiding transplant decisions in multiple myeloma with MRD
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
Advancements in paediatric Acute lymphoblastic leukemia management
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma In Rwanda: The need for further research
EHA 2024: Multiple myeloma roundup
Multiple myeloma in a resource constrained setting
